The association of speckle-type POZ protein with lymph node metastasis and prognosis in cancer patients: A meta-analysis.

ABSTRACT: BACKGROUND:Speckle-type POZ protein (SPOP) has recently been reported as a prognostic tumor biomarker. However, the predictive value of SPOP remains controversial in human cancers. The current meta-analysis was performed to obtain a comprehensive evaluation of the relationship between SPOP expression and prognosis of cancer patients. METHODS:Embase, Pubmed, Web of Science, and Chinese Biomedical Literature database were systematically searched up to January 2, 2019. The pooled hazard ratios (HRs) and/or pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to quantitatively assess the relationship of SPOP expression with prognosis and lymph node metastasis (LNM). RESULTS:A total of 9 studies with 928 patients were included in this meta-analysis. The results showed that low SPOP expression was significantly related to poor overall survival (high/low: HR?=?0.55; 95% CI: 0.38-0.79, P?=?.001), especially for digestive system cancers (high/low: HR?=?0.46; 95% CI: 0.27-0.78, P?=?.003). However, SPOP expression did not affect progression-free survival in cancer patients (high/low: HR?=?2.07; 95% CI: 0.16-26.70, P?=?.578). Additionally, the association between SPOP overexpression and LNM was positive in patients with clear cell renal cell carcinoma (ccRCC) (OR?=?5.26; 95% CI: 1.66-16.68, P?=?.005) but negative in cancer patients without ccRCC (OR?=?0.36; 95% CI: 0.21-0.62, P?

SUBMITTER: Cheng F 

PROVIDER: S-EPMC6783248 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature